What Happens in Vegas: PEP to PrEP Opportunities

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-01

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study looking at barriers to care for individuals seeking care, Post Exposure Prophylaxis (PEP) after an actual or perceived exposure to HIV. Following PEP treatment subjects will be asked about there intent to transition to Pre-Exposure Prophylaxis (PrEP) and surveyed about barriers to care or perceptions of care

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Implementation of the Phoenix PrEP (Pre-Exposure Prophylaxis) Access Project for Youth Aged 13-24

NCT03637322

Unsafe Sex IV Drug Usage

COMPLETED

IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project

NCT03058835

PrEP Adherence Monitoring

ACTIVE_NOT_RECRUITING PHASE4

Identification of the Pre-exposure Prophylaxis (PrEP) Cascade for Women.

NCT03705663

Pre-Exposure Prophylaxis

COMPLETED

Alignment of PrEP Use With HIV Risk in Young Women and Men

NCT04664998

Pre-Exposure Prophylaxis Sexually Transmitted Diseases, Bacterial HIV Infections

COMPLETED PHASE4

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation

NCT03253757

HIV Infections

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to assess the rate of engagement in a PEP to PrEP HIV provider network for those patients presenting following a non-occupational HIV exposure.

The development of a referral network and intensive clinical follow up of PEP patients will result in more patients appropriately initiating PEP, being referred to appropriate follow up, and post exposure transition and maintaining on PrEP (if indicated) at completion of the PEP medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exposure to Human Immunodeficiency Virus (Event)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Currently approved medications

subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Actual or perceived non-occupational exposure to HIV, by self report, within 72 hours of enrollment and referred for care
* able and willing to provide informed consent
* available for 12 months of post expoure follow-up Southern Nevada Ryan White defined service area

Exclusion Criteria

* HIV+ at time of screeing via 4th genderation (Antibody/Antigen) testing
* Current PEP and/or PrEP product condrainidications as listed in the medication product insert.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No